Verastem reports 2-year RAMP 201 data for avutometinib-defactinib combo in recurrent low-grade serous ovarian cancer

Bitget2026/09/28 20:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Verastem highlighted a
Gynecologic Oncology
publication with two-year follow-up from its Phase 2 RAMP 201 study in recurrent LGSOC.
Results were previously presented at the Society of Gynecologic Oncology 2026 annual meeting, then published online ahead of October 2026 print.
Follow-up data reinforced durable responses and disease control for the avutometinib-defactinib co-pack across KRAS-mutated and KRAS wild-type patients.
Safety and tolerability remained consistent with earlier findings, with no new safety signals reported.
Study data supported FDA accelerated approval for treating KRAS-mutated recurrent LGSOC following prior systemic therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609281610BIZWIRE_USPR_____20260928_BW878351) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Verastem reports 2-year RAMP 201 data for avutometinib-defactinib combo in recurrent low-grade serous ovarian cancer

You may also like

Crypto prices